Answers are grounded in this paper and cite their sources.
Validation of a 0.242 methylation cutoff improves prognostic predictions in glioblastoma, suggesting its role in clinical decision-making.
The identified qMSP cut-off value (0.242) based on the procedure described in this study provides a robust prognostic stratification tool for GBM patients. High MGMT methylation correlates with improved survival, supporting its integration into clinical decision-making. Further multi-center validation studies are warranted to establish standardized MGMT assessment methodologies.
No takes yet. Share an insight, caveat, or question.
Hüseyinoglu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: